Clinical remission of rheumatoid arthritis in a multicenter real-world study in Asia-Pacific region

[1]  H. Bliddal,et al.  Predictors of joint damage progression and stringent remission in patients with established rheumatoid arthritis in clinical remission. , 2020, Rheumatology.

[2]  A. Sahmoun,et al.  DAS28‐CRP Cutoffs for High Disease Activity and Remission Are Lower Than DAS28‐ESR in Rheumatoid Arthritis , 2020, ACR open rheumatology.

[3]  M. Dougados,et al.  Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial , 2020, The Lancet.

[4]  J. Xu,et al.  Effect of sustained intensive therapy with disease modifying anti-rheumatic drugs in rheumatoid arthritis: a 5-year real-world consecutive study , 2020, Chinese medical journal.

[5]  Tsutomu Takeuchi,et al.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update , 2020, Annals of the Rheumatic Diseases.

[6]  J. Smolen,et al.  Differences in disease activity measures in patients with rheumatoid arthritis who achieved DAS, SDAI, or CDAI remission but not Boolean remission. , 2020, Seminars in arthritis and rheumatism.

[7]  J. Baker,et al.  Sex Differences in the Achievement of Remission and Low Disease Activity in Rheumatoid Arthritis , 2020, Arthritis care & research.

[8]  Jinxia Zhao,et al.  Clinical deep remission and related factors in a large cohort of patients with rheumatoid arthritis , 2019, Chinese medical journal.

[9]  V. Shobha,et al.  Factors influencing remission in rheumatoid arthritis patients: results from Karnataka rheumatoid arthritis comorbidity (KRAC) study , 2016, International journal of rheumatic diseases.

[10]  Xiangpei Li,et al.  Remission assessment of rheumatoid arthritis in daily practice in China: a cross-sectional observational study , 2018, Clinical Rheumatology.

[11]  R. Buchbinder,et al.  Factors associated with oral glucocorticoid use in patients with rheumatoid arthritis: a drug use study from a prospective national biologics registry , 2017, Arthritis Research & Therapy.

[12]  M. Dougados,et al.  Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis , 2017, Annals of the rheumatic diseases.

[13]  E. Lee,et al.  Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial , 2016, Annals of the rheumatic diseases.

[14]  G. Littlejohn,et al.  Patients with Rheumatoid Arthritis in the Australian OPAL Cohort Show Significant Improvement in Disease Activity over 5 Years: A Multicenter Observational Study , 2015, The Journal of Rheumatology.

[15]  Inge Christoffer Olsen,et al.  Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000–2010 , 2013, Annals of the rheumatic diseases.

[16]  E. Keystone,et al.  Earlier Time to Remission Predicts Sustained Clinical Remission in Early Rheumatoid Arthritis — Results from the Canadian Early Arthritis Cohort (CATCH) , 2014, The Journal of Rheumatology.

[17]  M. Hetland,et al.  Monitoring patients with rheumatoid arthritis in routine care: experiences from a treat-to-target strategy using the DANBIO registry. , 2014, Clinical and experimental rheumatology.

[18]  P. Narongroeknawin,et al.  The good EULAR response at the first year is strongly predictive of clinical remission in rheumatoid arthritis: results from the TARAC cohort , 2014, Clinical Rheumatology.

[19]  I. Hafström,et al.  Long-term sustained remission in a cohort study of patients with rheumatoid arthritis: choice of remission criteria , 2013, BMJ Open.

[20]  D. M. van der Heijde,et al.  Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase IIIb, multinational, prospective, randomized study , 2013, Arthritis and rheumatism.

[21]  F. Wolfe,et al.  Remission of rheumatoid arthritis in clinical practice: application of the American College of Rheumatology/European League Against Rheumatism 2011 remission criteria. , 2011, Arthritis and rheumatism.

[22]  D. Symmons,et al.  Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008 , 2010, Rheumatology.

[23]  D. M. van der Heijde,et al.  Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research , 2008, Annals of the rheumatic diseases.

[24]  T. Pincus,et al.  RAPID3 (Routine Assessment of Patient Index Data 3), a Rheumatoid Arthritis Index Without Formal Joint Counts for Routine Care: Proposed Severity Categories Compared to Disease Activity Score and Clinical Disease Activity Index Categories , 2008, The Journal of Rheumatology.

[25]  T. Pincus,et al.  Remission and rheumatoid arthritis: data on patients receiving usual care in twenty-four countries. , 2008, Arthritis and rheumatism.

[26]  Brijal Dave,et al.  Kimura disease with proliferative squamous metaplasia: an unusual finding and a potential diagnostic pitfall. , 2007, Indian journal of pathology & microbiology.

[27]  F. Wolfe,et al.  Minimal disease activity, remission, and the long-term outcomes of rheumatoid arthritis. , 2007, Arthritis and rheumatism.

[28]  M. Uffmann,et al.  Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score , 2005, Arthritis research & therapy.

[29]  P. Tugwell,et al.  A simplified disease activity index for rheumatoid arthritis for use in clinical practice. , 2003, Rheumatology.

[30]  M. Prevoo,et al.  Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. , 1995, Arthritis and rheumatism.